On September 24, HANSOH PHARMA fell 3.09% in regular trading, trading at HKD 33.86 per share, with turnover of HKD 41.39 million. The decline came amid broad-based selling pressure across the pharmaceuticals sector, despite a string of positive company-specific catalysts in recent weeks.

The wider pharmaceutical industry saw widespread weakness during the session. Among major sector peers, CSPC Pharma fell 1.97%, China Biopharmaceutical dropped 2.55%, Asymchem declined 4.58%, and Hengrui Pharma slid 2.80%, while HUTCHMED edged up 0.27%. The sector-wide downdraft overshadowed HANSOH PHARMA's recent positive developments, including its HS-20093 osteosarcoma indication gaining NMPA priority review on September 22, and the Phase 3 success of its TYK2 inhibitor HS-10374 for moderate-to-severe plaque psoriasis announced on September 21. Multiple investment banks have maintained buy ratings on the stock, with target prices ranging from HKD 43.70 to HKD 52.70, suggesting significant upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)